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Control DOB DOB + RAP
MV02 diameter MV02 %~ in MV02 %.1. in({Lm) diameter diameter
Normal 11 ±1 60 ± 5 23 ± 2 24 ± 4 39 ± 7 43 ± 6
OM 21 ± 7 78 ± 6 36 ± 13 17 ± 5 40± 13 14± 3'
OM + SO 16 ± 3 82 ± 9 22 ± 1 20± 3 41 ± 5 37 ± 7
Richard F. Ammar, Jr., David D. Gutterman, Kevin C. Dellsperger. University of Iowa,
Iowa City, IA
Our laboratory has previously demonstrated that nitric oxide (NO) medi-
ates coronary arteriolar dilation to increased myocardial oxygen consump-
tion (MV02). NO mediated dilation has been shown to be attenuated in di-
abetes (OM), and endoperoxide antagonists restore this dilation to normal.
We, therefore, studied the effect of OM on metabolically mediated dilation
of coronary arterioles. We further tested the effect of S029548 (SO; throm-
boxane A2 and prostaglandin H2 receptor antagonist) on coronary arterio-
lar dilatory responses to increased MV02 in OM. We measured changes
in epicardial arteriolar diameters in 5 OM (1 week alloxan, 60 mglkg, iv), 4
OM after administration of SO (2 mglkg. iv), and 6 normal dogs during in-
creased MV02, using dobutamine (DOB; 10{Lglkg/min. iv) with rapid atrial
pacing (RAP; 288 ± 4 bpm). Diameters were measured using intravital mi-
croscopy in anesthetized dogs with stroboscopic epi-illumination coupled to
the cardiac cycle. Mean aortic pressure and blood gases were monitored
and kept constant throughout the protocol. Results:
Background: A polymorphic marker of the ACE gene has been related to
Methods and Results: We therefore studied the effects of intracoronary
acetylcholine (ACh), which stimulates the endothelial release of EDRF, on
blood flow and platelet cGMP content in 14 patients with agiographically
normal coronary arteries undergoing cardiac catheterization. Seven patients
received sodium nitroprusside (SNP) infusions. Blood flow was derived from
Doppler flow velocity, and diameter was measured by quantitative angiog-
raphy. Simultaneous samples were drawn from the great cardiac vein for
measurement of platelet cGMP content by radioimmunoassay. During ACh
infusion (30 {Lg/min} there was a transient increase in both coronary flow
138 ± 25% (mean ± SEM, p < 0.01) and platelet cGMP content (34 ± 13%.
p < 0.01). that returned to baseline (both p < 0.01). Epicardial diameter re-
sponses to ACh were heterogenous: seven patients showed constriction
(-7 ± 2%) and seven showed dilatation (11 ± 2%). Changes in platelet cGM P
content and epicardial diameter paralleled each other: in patients with di-
latation. ACh increased cGMP content significantly (54 ± 22%, P < 0.02),
whereas in those with constriction the change in cGMP was insignificant (14
± 8%, P = NS). During SNP infusion (40 {Lg/min) flow increased by 127 ±
23% and cGMP content by 226 ± 55% (p < 0.02).
Conclusions: 1) luminal release of EDRF in the human coronary circula-
tion causes an increase in platelet cGMP content; 2) this effect is less evi-
dent in patients with impaired endothelial-mediated vasodilation. Failure of
this platelet inhibitory effect in patients with atherosclerosis and endothelial
dysfunction may contribute to their increased susceptibility to thrombotic
vascular events.
mean ± SEM, • P < 0.05 vs. Normal. MV02 is ml/min/100 9
In OM animals, during DOB + RAP. arterial-venous oxygen difference in-
creased as flow decreased. thus keeping MVOz similar. Thus, coronary arteri-
oles in diabetes demonstrate attenuated microvascular dilation to increased
myocardial oxygen consumption. and vasoconstrictor endoperoxides playa
key role in this impaired response.
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Superoxide anion (°2-), a moiety that rapidly inactivates nitric oxide, is
present in elevated concentrations in the vessel wall following balloon vas-
cular injury. Recent data suggest that 02- is involved in the abnormal
endothelium-dependent vasomotor responses of the regenerated endothe-
lium.
To investigate the hypothesis that polyethyleneglycol superoxide dismu-
tase (PEG-SOD) can effectively scavenge 02- in the vessel wall, ten pigs
were subjected to balloon injury of the left anterior descending or left circum-
flex coronary artery, then maintained on normal lab diets for 28 days. On day
29 five pigs (RX group) began receiving daily intravenous infusions of PEG-
SOD (12,000 Ulkg day 1, then 6,000 Ulkg days 2-5) while five pigs received no
PEG-SOD therapy (NO RX group). All animals were sacrificed on day33. 02-
generation was assessed by lucigenin-amplified chemiluminescence in seg-
ments of injured and uninjured coronary arteries. Uninjured/NO RX segments
(n = 7) and uninjured/RX segments (n = 7) had similar 02- levels (2728 ±
457 and 3540 ± 543 counts per minute/mg tissue dry weight, respectively, p
= NS). Injured/NO RX segments (n = 5) had significantly elevated 02- pro-
duction (7040 ± 1608 cpm/mg, p < 0.05 vs baseline). PEG-SOD therapy in in-
jured/RX segments (n = 7) dramatically restored 02- levels to normal (3167
± 681 cpm/mg, p = NS vs uninjured, p < 0.05 vs injured/NO AX).
Thus. PEG-SOD therapy effectively reduces 02- levels in the vessel wall
following balloon injury. Prevention of nitric oxide degradation via this mech-
anism may have important implications for modulation of coronary vascular
tone following balloon injury.
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Enhanced interaction of mononuclear cells with the endothelium is the
first observable event in the development of atherosclerosis. Hypercholes-
terolemia reduces vascular nitric oxide activity. This dysfunction may pro-
mote endothelial monocyte interaction, as NO is a potent inhibitor of ad-
hesion. We have previously shown that dietary L-arginine (Arg) supple-
mentation in hypercholesterolemic rabbits restores NO activity and inhibits
monocyte-endothelial cell interaction, in association with a reduction in
atherogenesis. Accordingly we developed a functional binding assay to as-
sess the adhesiveness of human mononuclear cells. so as to determine the
effects of hypercholesterolemia and L-arginine therapy. We found a 50% in-
crease in adhesion of mononuclear cells (MNC) from hypercholesterolemic
(HC) subjects to cultured endothelial cells ex vivo compared to a normo-
cholesterolemic control population (p < 0.0001. n = 20). Increased MNC
adhesion was reversed to normal levels by preincubation of the MNC sus-
pension with 10-5 M sodium nitroprusside (164.4 ± 8.7% vs 97.5 ± 6.9%,
P < 0.0005, n = 7). while L-nitroarginine and Arg did not have an effect in
vitro. In a double-blinded placebo-controlled study, oral Arg (8.4 g/day) was
administered to 7 HC subjects. Over a course of two weeks, this treatment
abolished the increased adhesion (158.5 ± 10.9% vs 103.5 ± 4.9% vs 100 ±
5.2%, HCvs Arg vs Control. p < 0.005), while MNC adhesion remained signif-
icantlyelevated in placebo-treated subjects. Conclusion: The adhesiveness
of human mononuclear cells is increased by hypercholesterolemia. The in-
crease in adhesiveness is reversed in vitro by NO donors, and reversed in
vivo by treatment with the NO precursor L-arginine.
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Introduction: Endothelium-derived relaxing factor (EDAFI inhibits platelet ac-
tivation by increasing platelet cyclic GMP content. In the human coronary
circulation the vasodilator effect of EDRF released abluminally from the en-
dothelium is well described. but the effects of luminal release of EDRF
on platelets is unknown. Furthermore, whether decreased vasodilator re-
sponses to agents that stimulate EDRF release are also associated with an
abnormal platelet response is unknown.
